The TAFFD’s family is expanding rapidly as kin interest from well-meaning academics and bodies, especially those with emerging thoughts draws near. As institutions, bodies, organizations and movements partner with TAFFD’s, endorsing all that they do, there are lots more to come.
With this in mind, Dr. Aubrey de Grey emerges as the grand patron of TAFFD’s globally.
Who is Aubrey de Grey?
Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing new therapies in the field of biomedical gerontology. In addition, he is Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging. He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.
The TAFFD’s family tips Aubrey because of his openness to new ideas. Amidst that, Aubrey is humble and he gives a listening ear with incredible patience when it comes to leading. Looking at his advisory technique, one can see, Moral and Spiritual Support.
We thank him for accepting to be a grand patron to this family as we are set to announce other patrons.